Barclays initiated coverage of Intellia Therapeutics (NTLA) with an Underweight rating, signaling a bearish view on the CRISPR-focused biotech. No price target was disclosed.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
